182 related articles for article (PubMed ID: 29741503)
1. A closer look at copanlisib.
Dreyling M
Clin Adv Hematol Oncol; 2018 Jan; 16(1):35-37. PubMed ID: 29741503
[No Abstract] [Full Text] [Related]
2. Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M; Cheson BD
Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
[TBL] [Abstract][Full Text] [Related]
3. [Molecular targeted therapy for malignant brain tumors].
Okamura T; Kurisu K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
[No Abstract] [Full Text] [Related]
4. A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Doi T; Fuse N; Yoshino T; Kojima T; Bando H; Miyamoto H; Kaneko M; Osada M; Ohtsu A
Cancer Chemother Pharmacol; 2017 Jan; 79(1):89-98. PubMed ID: 27915408
[TBL] [Abstract][Full Text] [Related]
5. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
[TBL] [Abstract][Full Text] [Related]
6. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
7. Targeting PI3K Signaling in Combination Cancer Therapy.
Pons-Tostivint E; Thibault B; Guillermet-Guibert J
Trends Cancer; 2017 Jun; 3(6):454-469. PubMed ID: 28718419
[TBL] [Abstract][Full Text] [Related]
8. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
9. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
Dancey JE; Schoenfeldt M
Oncology (Williston Park); 2001 Jun; 15(6):748-50, 756-8. PubMed ID: 11430207
[No Abstract] [Full Text] [Related]
10. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
11. Copanlisib: First Global Approval.
Markham A
Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
[TBL] [Abstract][Full Text] [Related]
12. The cancer stem cell gamble.
Kaiser J
Science; 2015 Jan; 347(6219):226-9. PubMed ID: 25593170
[No Abstract] [Full Text] [Related]
13. Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.
Brose MS
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 9):7-12. PubMed ID: 27168342
[No Abstract] [Full Text] [Related]
14. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Morschhauser F; Machiels JP; Salles G; Rottey S; Rule SAJ; Cunningham D; Peyrade F; Fruchart C; Arkenau HT; Genvresse I; Liu L; Köchert K; Shen K; Kneip C; Peña CE; Grevel J; Zhang J; Cisternas G; Reschke S; Granvil C; Awada A
Mol Cancer Ther; 2020 Feb; 19(2):468-478. PubMed ID: 31619463
[TBL] [Abstract][Full Text] [Related]
15. Combinations of targeted therapies take aim at multiple pathways.
Goldman B
J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255
[No Abstract] [Full Text] [Related]
16. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
17. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Cheson BD; O'Brien S; Ewer MS; Goncalves MD; Farooki A; Lenz G; Yu A; Fisher RI; Zinzani PL; Dreyling M
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):135-141. PubMed ID: 30584024
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline compounds for antitumor treatment.
Solyanik GI
Exp Oncol; 2019 Mar; 41(1):3-6. PubMed ID: 30932417
[TBL] [Abstract][Full Text] [Related]
19. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
20. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
